All data are based on the daily closing price as of October 8, 2025
s

Santen Pharmaceutical

4536.TSE
10.33 USD
-0.08
-0.77%

Overview

Last close
10.33 usd
Market cap
3.39B usd
52 week high
12.72 usd
52 week low
8.93 usd
Target price
14.04 usd

Valuation

P/E
15.3011
Forward P/E
13.4409
Price/Sales
1.8227
Price/Book Value
1.912
Enterprise Value
2.96B usd
EV/Revenue
1.5061
EV/EBITDA
7.6571

Key financials

Revenue TTM
1.92B usd
Gross Profit TTM
1.08B usd
EBITDA TTM
402.15M usd
Earnings per Share
0.68 usd
Dividend
0.24 usd
Total assets
2.83B usd
Net debt
-586.98M usd

About

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative filed for marketing approval for the treatment of glaucoma and ocular hypertension; and epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval to treat allergic conjunctivitis. The company also offers netarsudil mesylate/latanoprost, a fixed dose combination drug of a ROCK inhibitor and a prostaglandin F2a derivative which is in phase III clinical trial for the treatment of glaucoma and ocular hypertension; and sepetaprost, a prostaglandin analogue eye drop drug that is in phase III clinical trials for the treatment of glaucoma and ocular hypertension. In addition, it develops oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase III clinical trial for treatment of ptosis; and omidenepag isopropyl, an EP2 receptor agonist that is in phase III clinical trial for the treatment of glaucoma and ocular hypertension. Further, the company offers atropine sulfate, a non-selective muscarinic antagonist that is in phase II/III clinical trials for the treatment of juvenile myopia; olodaterol hydrochloride, a ß2 receptor agonist that has completed phase 1/2a clinical trial for the treatment of a dry eye; and sirolimus, an ophthalmic suspension which is in phase 2a clinical trial for the treatment of fuchs endothelial corneal dystrophy and meibomian gland dysfunction. The company was founded in 1890 and is headquartered in Osaka, Japan.
  • Symbol
    4536.TSE
  • Exchange
    TSE
  • Isin
    JP3336000009
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - General
  • CEO
    Mr. Takeshi Ito
  • Headquarter
    Osaka
  • Web site
    https://www.santen.com/en
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top